Results 11 to 20 of about 41,565 (267)

Natalizumab for relapsing-remitting multiple sclerosis

Neurología (English Edition), 2011
Introduction: Natalizumab is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier and has been approved for the treatment of relapsing-remitting multiple sclerosis.
A. Horga, M. Tintoré
doaj   +3 more sources

Postural Control in Relapsing-Remitting Multiple Sclerosis [PDF]

International Archives of Otorhinolaryngology, 2022
Introduction Postural instability is considered one of the most disabling symptoms of relapsing-remitting multiple sclerosis (RRMS). Objective To evaluate postural control in patients with RRMS.
Flavia Salvaterra Cusin, Andreza Tomaz, Maurício Malavasi Ganança, Enedina Maria Oliveira, Alessandra Billi Falcão Gonçalves, Heloisa Helena Caovilla   +5 more
doaj   +4 more sources

Interferon in relapsing-remitting multiple sclerosis [PDF]

Cochrane Database of Systematic Reviews, 2001
Recombinant interferons have been shown to suppress both the clinical and magnetic resonance imaging (MRI) measures of disease activity in patients with relapsing remitting multiple sclerosis (RRMS).We performed a Cochrane review of all randomised, placebo-controlled trials of recombinant interferons in RRMS.Of 208 articles identified by a predefined ...
George PA Rice, Barbara Incorvaia, Luca M. Munari, George Ebers, Chris Polman, Roberto D'Amico, Elena Parmelli, Graziella Filippini   +7 more
openaire   +3 more sources

Natalizumab for relapsing remitting multiple sclerosis [PDF]

Cochrane Database of Systematic Reviews, 2009
Natalizumab (NTZ) (Tysabri(®)) is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier, thus reducing inflammation in central nervous system, and has been approved worldwide for the treatment of relapsing-remitting multiple sclerosis (RRMS).To evaluate the efficacy, tolerability and safety of NTZ in the treatment of ...
Pucci, Eugenio, Giuliani, Giorgio, Solari, Alessandra, Simi, Silvana, Minozzi, Silvia, Di Pietrantonj, Carlo, Galea, Ian   +6 more
openaire   +4 more sources

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis [PDF]

Neurotherapeutics, 2018
Changes of intestinal permeability (IP) have been extensively investigated in inflammatory bowel diseases (IBD) and celiac disease (CD), underpinned by a known unbalance between microbiota, IP and immune responses in the gut. Recently the influence of IP on brain function has greatly been appreciated. Previous works showed an increased IP that preceded
Buscarinu, M. C., Romano, S., Mechelli, R., Pizzolato Umeton, R., Ferraldeschi, M., Fornasiero, A., ReniÃ, R., Cerasoli, B., MORENA, EMANUELE, Romano, Carmela, Loizzo, N. D., Umeton, R., Salvetti, M., Ristori, G.   +13 more
openaire   +3 more sources

Predicting the On-Study Relapse Rate for Multiple Sclerosis Patients in Clinical Trials [PDF]

, 2005
Background: The annual relapse rate has been commonly used as a primary efficacy endpoint in phase III multiple sclerosis (MS) clinical trials. The aim of this study was to determine the relative contribution of different possible prognostic factors ...
Chang, C., Polman, Chris, Kappos, L., Polman, C., Held, U., Heigenhauser, L., Shang, C., Heigenhauser, Ludwig, Kappos, Ludwig   +8 more
core   +1 more source

Multiple Sclerosis Relapsing Remitting Progressive Type

Jurnal Profesi Medika, 2020
Multiple sclerosis (MS) is the most common neurologic demyelinating disease in high-income countries. The causes of MS is multifactorial involve genetics and the environment in which immune cell infiltration occurs across the blood-brain barrier, causing
Nora Fitri, Basjiruddin Ahmad, Yuliarni Syafrita   +2 more
doaj   +1 more source

Presence and significant determinants of cognitive impairment in a large sample of patients with Multiple Sclerosis [PDF]

, 2013
This work was supported by FISM - Fondazione Italiana Sclerosi Multipla (www.aism.it) - Cod. 2009/R/17.Objectives: To investigate the presence and the nature of cognitive impairment in a large sample of patients with Multiple Sclerosis (MS), and to ...
Cavallo, Marco, Picci, Rocco Luigi, Simona Malucchi, Furlan, Piermaria, Malucchi, Simona, Ostacoli, Luca, Johnston, Harriet, Bertolotto, Antonio, Rocco Luigi Picci, Francesco Scavelli, Carletto, Sara, Marco Cavallo, Cavallo, M, Borghi, Martina, Furlan, Pier Maria, Scavelli, Francesco, Martina Borghi, Pier Maria Furlan, Antonio Bertolotto, Harriet Johnston, Zuffranieri, Marco, Luca Ostacoli, Marco Zuffranieri, Sara Carletto   +23 more
core   +1 more source

Modern Technology in Multi-Shell Diffusion MRI Reveals Diffuse White Matter Changes in Young Adults With Relapsing-Remitting Multiple Sclerosis

Frontiers in Neuroscience, 2021
ObjectiveTo characterize microstructural white matter changes related to relapsing-remitting multiple sclerosis using advanced diffusion MRI modeling and tractography.
Ann-Marie Beaudoin, François Rheault, Guillaume Theaud, Frédéric Laberge, Kevin Whittingstall, Albert Lamontagne, Maxime Descoteaux   +6 more
doaj   +1 more source

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a. [PDF]

, 2004
S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled ...
Lim, Ee Tuan, Leary, Siobhan M, Geoff Keir, Petzold, Axel, Thompson, Alan J, Gavin Giovannoni, Siobhan M Leary, Altmann, Daniel R, Keir, Geoff, Ee Tuan Lim, David H Miller, Ed J Thompson, Giovannoni, Gavin, Miller, David H, Alan J Thompson, Daniel R Altmann, Thompson, Ed J, Axel Petzold   +17 more
core   +1 more source